These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 28622868)

  • 1. Vaccination against porcine reproductive and respiratory syndrome virus (PRRSV) reduces the magnitude and duration of viremia following challenge with a virulent heterologous field strain.
    Calvert JG; Keith ML; Pearce DS; Lenz MC; King VL; Diamondidis YA; Ankenbauer RG; Martinon NC
    Vet Microbiol; 2017 Jun; 205():80-83. PubMed ID: 28622868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection and immune response in pigs intradermally vaccinated against porcine reproductive and respiratory syndrome (PRRS) and subsequently exposed to a heterologous European (Italian cluster) field strain.
    Martelli P; Cordioli P; Alborali LG; Gozio S; De Angelis E; Ferrari L; Lombardi G; Borghetti P
    Vaccine; 2007 Apr; 25(17):3400-8. PubMed ID: 17276558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A porcine reproductive and respiratory syndrome virus candidate vaccine based on the synthetic attenuated virus engineering approach is attenuated and effective in protecting against homologous virus challenge.
    Evenson D; Gerber PF; Xiao CT; Halbur PG; Wang C; Tian D; Ni YY; Meng XJ; Opriessnig T
    Vaccine; 2016 Nov; 34(46):5546-5553. PubMed ID: 27742217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity.
    Martelli P; Gozio S; Ferrari L; Rosina S; De Angelis E; Quintavalla C; Bottarelli E; Borghetti P
    Vaccine; 2009 Jun; 27(28):3788-99. PubMed ID: 19442420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy of a new modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS) against heterologous PRRSV challenge.
    Park C; Seo HW; Han K; Kang I; Chae C
    Vet Microbiol; 2014 Aug; 172(3-4):432-42. PubMed ID: 24970363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response and protective efficacy of intramuscular and intradermal vaccination with porcine reproductive and respiratory syndrome virus 1 (PRRSV-1) modified live vaccine against highly pathogenic PRRSV-2 (HP-PRRSV-2) challenge, either alone or in combination with of PRRSV-1.
    Madapong A; Saeng-Chuto K; Chaikhumwang P; Tantituvanont A; Saardrak K; Pedrazuela Sanz R; Miranda Alvarez J; Nilubol D
    Vet Microbiol; 2020 May; 244():108655. PubMed ID: 32402335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of simultaneous vaccination with two modified live virus vaccines against porcine reproductive and respiratory syndrome virus types 1 and 2 in pigs.
    Kristensen CS; Kvisgaard LK; Pawlowski M; Holmgaard Carlsen S; Hjulsager CK; Heegaard PMH; Bøtner A; Stadejek T; Haugegaard S; Larsen LE
    Vaccine; 2018 Jan; 36(2):227-236. PubMed ID: 29191738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commercial porcine reproductive and respiratory syndrome virus (PRRSV)-2 modified live virus vaccine against heterologous single and dual Korean PRRSV-1 and PRRSV-2 challenge.
    Jeong J; Kim S; Park C; Park KH; Kang I; Park SJ; Chae C
    Vet Rec; 2018 Apr; 182(17):485. PubMed ID: 29472439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmission of Porcine reproductive and respiratory syndrome virus 1 to and from vaccinated pigs in a one-to-one model.
    Pileri E; Gibert E; Martín-Valls GE; Nofrarias M; López-Soria S; Martín M; Díaz I; Darwich L; Mateu E
    Vet Microbiol; 2017 Mar; 201():18-25. PubMed ID: 28284607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a modified-live virus vaccine in pigs experimentally infected with a highly pathogenic porcine reproductive and respiratory syndrome virus type 1 (HP-PRRSV-1).
    Canelli E; Catella A; Borghetti P; Ferrari L; Ogno G; De Angelis E; Bonilauri P; Guazzetti S; Nardini R; Martelli P
    Vet Microbiol; 2018 Nov; 226():89-96. PubMed ID: 30389048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
    Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
    Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and performance impact of Fostera PRRS in a Vietnamese commercial pig farm naturally challenged by a highly pathogenic PRRS virus.
    Do DT; Nguyen TT; Nguyen NTH; Nguyen MHP; Le HT; Nguyen NTT; Nguyen NTP; Chae C; Mah CK
    Trop Anim Health Prod; 2020 Jul; 52(4):1725-1732. PubMed ID: 31898019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pigs immunized with Chinese highly pathogenic PRRS virus modified live vaccine are protected from challenge with North American PRRSV strain NADC-20.
    Galliher-Beckley A; Li X; Bates JT; Madera R; Waters A; Nietfeld J; Henningson J; He D; Feng W; Chen R; Shi J
    Vaccine; 2015 Jul; 33(30):3518-25. PubMed ID: 26049004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model.
    Pileri E; Gibert E; Soldevila F; García-Saenz A; Pujols J; Diaz I; Darwich L; Casal J; Martín M; Mateu E
    Vet Microbiol; 2015 Jan; 175(1):7-16. PubMed ID: 25439650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs.
    Fontanella E; Ma Z; Zhang Y; de Castro AM; Shen H; Halbur PG; Opriessnig T
    Vaccine; 2017 Jan; 35(1):125-131. PubMed ID: 27876202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Fostera® PRRS modified live virus (MLV) vaccination strategy against a Thai highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) infection.
    Charoenchanikran P; Kedkovid R; Sirisereewan C; Woonwong Y; Arunorat J; Sitthichareonchai P; Sopipan N; Jittimanee S; Kesdangsakonwut S; Thanawongnuwech R
    Trop Anim Health Prod; 2016 Oct; 48(7):1351-9. PubMed ID: 27315207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of saponin quil A and PRRSV-1 modified-live virus vaccine up-regulates gene expression of type I interferon-regulated gene, type I and II interferon, and inflammatory cytokines and reduces viremia in response to PRRSV-2 challenge.
    Charerntantanakul W; Pongjaroenkit S
    Vet Immunol Immunopathol; 2018 Nov; 205():24-34. PubMed ID: 30458999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-protection of a new type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccine (Fostera PRRS) against heterologous type 1 PRRSV challenge in growing pigs.
    Park C; Choi K; Jeong J; Chae C
    Vet Microbiol; 2015 May; 177(1-2):87-94. PubMed ID: 25769646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with a Porcine Reproductive and Respiratory Syndrome (PRRS) Modified Live Virus Vaccine Followed by Challenge with PRRS Virus and Porcine Circovirus Type 2 (PCV2) Protects against PRRS but Enhances PCV2 Replication and Pathogenesis Compared to Results for Nonvaccinated Cochallenged Controls.
    Niederwerder MC; Bawa B; Serão NV; Trible BR; Kerrigan MA; Lunney JK; Dekkers JC; Rowland RR
    Clin Vaccine Immunol; 2015 Dec; 22(12):1244-54. PubMed ID: 26446422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge.
    Van Noort A; Nelsen A; Pillatzki AE; Diel DG; Li F; Nelson E; Wang X
    Virol J; 2017 Apr; 14(1):76. PubMed ID: 28403874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.